Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.

9007Background: TAK-788 is an oral investigational EGFR/HER2 inhibitor under evaluation in NSCLC patients (pts) with EGFR exon 20 insertions. We report results of a phase 1/2 open-label, multicente...